Incorporating a polygenic risk score into prostate cancer screening could enhance the detection of clinically significant prostate cancer that conventional screening may miss, according to results of ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

In a cohort of US veterans with prostate cancer who were on active surveillance, negative multiparametric MRI had a 75% negative predictive value for ruling out disease of grade group 2 or higher at ...

Targeting men in the top 10% of genetic risk helped detect high-grade prostate cancer that conventional screening would miss, paving the way for more personalized and effective early detection ...

Baseline MRI PI-RADS score suggests prognosis and may improve upfront risk stratification and eligibility for prostate cancer active surveillance. Higher baseline MRI PI-RADS score is associated with ...

The incidence of prostate cancer is increasing. Screening with an assay of prostate-specific antigen (PSA) has a high rate for false positive results. Genomewide association studies have identified ...

There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...

AI-driven MRI analysis offers new insights into prostate cancer prognosis, accurately predicting metastasis risk and treatment outcomes for improved patient care. Study: AI-derived Tumor Volume from ...